Description

WHAT IS RETATRUTIDE?

Retatrutide for weight loss: “Ozempic version 3.0” – the third-generation GLP-1 peptide

Retatrutide is the most recently developed drug in the “Ozempic family” (i.e., the class of drugs known as “glucagon-like peptide-1 analogs”).

It is a peptide composed of 39 amino acids.

Retatrutide is still in phase 2 clinical trials, while semaglutide (Wegovy) and tirzepatide (Mounjaro, Zepbound) are already approved for the treatment of obesity.

It has been shown to significantly reduce food intake and increase weight loss in clinical trials. In fact, it is even more promising than semaglutide (Ozempic) and tirzepatide (Mounjaro, Zepbound) in this regard. Here’s why:

1. Triple mechanism of action: Retatrutide acts on three hormones related to appetite and satiety (GLP-1, GIP, and glucagon), while tirzepatide acts on two (GLP-1 and GIP), and semaglutide on only one (GLP-1).
2. Greater weight loss: Phase 2 studies have shown that retatrutide results in greater weight loss compared to tirzepatide and semaglutide. On average, people using retatrutide lose 24% of their body weight, compared to 21% with tirzepatide and 17% with semaglutide.
3. Better tolerated: Phase 2 studies suggest that retatrutide is better tolerated than tirzepatide and semaglutide. This means people using it are less likely to experience side effects such as nausea, vomiting, diarrhea, or other digestive issues.

BENEFITS OF RETATRUTIDE

• Induces very significant weight loss in a short period of time
• Improves insulin sensitivity
• Reduces blood sugar levels
• Has far fewer side effects than other weight loss medications

PRODUCT PRESENTATION

6mg vial of Retatrutide HA by Limitless Life Nootropics – 99%+ purity.

HOW TO USE AND STANDARD DOSAGE

Reconstitute the vial with 2ml of bacteriostatic water.

PEOPLE WITH MILD OVERWEIGHT:

• Initial dose: 2 mg (equivalent to 0.67 ml of liquid) via subcutaneous injection once a week
• After 4 weeks: if weight loss is insufficient, the dose may be increased to 3 mg (equivalent to 1 ml of liquid) per week

PEOPLE WITH SEVERE OVERWEIGHT:

• Initial dose: 3 mg (equivalent to 1 ml of liquid) via subcutaneous injection once a week
• After 4 weeks: if weight loss is insufficient, the dose may be increased to 6 mg (equivalent to 2 ml of liquid) per week

TREATMENT DURATION

Once weight loss goals are achieved, there are two options:

• Discontinue treatment
• Continue with a low maintenance dose of 1.5 mg (equivalent to 0.5 ml of liquid) per week

Maximum dose: 15 mg per week